As we discussed above, MTA is not specific to Alzheimer disease; we do not have data on other markers of Alzheimer disease pathology (measures of Aβ and tau, eg, using positron emission tomography or cerebrospinal fluid) and therefore cannot comment further on the extent to which pathologies associated with Alzheimer disease contribute to our findings. This evidence concerns the gene MAPT and Alzheimer disease.